Acceleration of fetal maturation by intra-amniotic administration of thyroxine ADAMSONS,Κ., J.ROMAGUERA, R.C.WALLACH Spontaneously occurring Hyperthyroidism of the fetus secondary to transplacentally acquired LATS, has been known to accelerate markedly fetal maturation, including that of the skeletal system.
The purpose of this study was to examine the effectiveness of induced fetal hyperthyroidism upon the rate of fetal maturation among patients who were likely to go into pre-term labor, or in whom pre-term delivery hat been planned either for maternal or fetal indications .
The present report summarizes our experience of the initial 15 patients (Fig.1 (renal and CNS malformation) of one of the twins, triplet ge-~s t a t i o n , a n d pre-term rupture of membranes. Evaluation of mother and fetus prior to the administration of thyroxine. The assessment consisted of documentation of fetal age by history and sonographic measurements of the fetus, maternal T 3/ T 4 and TSH, frequency of fetal heart rate and fetal movements (as detected by mother), and composition of amniotic fluid (L/S, Creatinine and Bilirubin).
Thyroxine was injected into the amniotic space in doses ranging from 2OO to 5OO mg and was repeated either weekly or in a 3 day interval.
The indicators used to assess the impact of thyroxine therapy upon mother and fetus were identical with those used for initial assessment, except for signs and symptoms suggestive of maternal hyperthyroidism (eq. palpitations, anxiety and insomnia).
Only 3 of the 15 mothers displayed signs of mild and transient hyperthyroidism which was observable 48 hours after the administration of the second dose and disappeared within 2 days.
There was an increase Of fetal movement (both frequency and intensity) all instances, which increase was noted first after 48 hours of the initial dose of thyroxine.
Heart rate of the fetus increased only ifioderately ranging from 5 to 2O beats per minute.
The pre-treatment L/S had a mean value of 1.16 and the mean of the gestational ge was 3O. 6 weeks ( Fig.2  and 3 
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an L/S 2 was 11.4 days, the median was only 7 days. In 2 patients a change of L/S from 1.43 ana 1.75 to 2.35 and 2. 6O respectively occurred in less than 4 days. P.G.Values were obtained on only one patient, in whom it changed from undetectable to 3.3 over a period of one week.
It is evident that L/S of the treated population differ markedly from those derived from a large control group (dotted line).
Although in one case L/S of 2.4 was observed at 29.6 weeks of gestation following 4 weeks of thyroxine therapy, in all others the principal change occurred between the 31 and 33 weeks. The lesser responsiveness of the younger fetuses might be explained on the basis of their limited capacity to transform the adminstered Tî nto Τ 3.
Effect on growth and general maturation of the fetus was assessed by comparing birth weight and DUBOWITZ scores against respective standards at matched gestational age. Reference standard for expected birth weight was 5O percentile of the LUBCHENKO nomogram.
The mean birth weight was 258 grams above that predicted from the nomogram, and the mean of the DUBOWITZ score was 2.26 weeks ahead of the chronologic age of the fetus.
Bone age was determined only on one infant; it was 3 weeks above the chronologic age. Neonatal complications consisted of mild RDS in 1 of 16 newborns, transient tachypnea in 3, and in-utero acquired pneumonia in 2.
Only two of the newborns required assisted ventilation. All newborns were enrolled in a special surveillance program under the direction of a pediatric endocrinologist. Follow-up to date has failed to disclose any unusual clinical problems. Only one of the 16 newborns received thyroxine postnatally for reasons unrelated to clinically detectable Hypothyroidism. None had suppressed TSH levels, or abnormal T 3 or T^ concentrations. The triplets exhibited an above average growth pattern for the first two months, and received blood transfusion for anemia.
Our inital experience supports the view that a relatively mild degree of fetal hyperthyroidism brought about by intraamniotic administration of thyroxine, accelerates fetal maturation, while at the same time increasing fetal growth. Thyroxine appears to be superior to glucocorticoids to prevent sequelae of immaturity.
It is probable that T3 is even more efficatious to achieve this objective than 14, due to the limited capacity of the younger fetus to transform T 4 into T 3 .
